NCT04973111View on ClinicalTrials.gov

A Study to Assess CT-868 and the Relationship Between Insulin Secretory Response and Ambient Blood Glucose

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

July 16, 2021

Primary Completion Date

April 22, 2022

Study Completion Date

April 22, 2022

Conditions
Diabetes
Interventions
DRUG

CT-868 as SC Injection

CT-868

DRUG

Placebo as SC Injection

Placebo

DRUG

Active Comparator as SC Injection

Active Comparator

Trial Locations (1)

91911

Carmot Clinical Research Unit 101, Chula Vista

Sponsors
All Listed Sponsors
lead

Carmot Therapeutics, Inc.

INDUSTRY